Literature DB >> 21798989

Aboriginal to non-Aboriginal differentials in 2-year outcomes following non-fatal first-ever acute MI persist after adjustment for comorbidity.

Judith M Katzenellenbogen1, Frank M Sanfilippo, Michael S T Hobbs, Tom G Briffa, Steve C Ridout, Matthew W Knuiman, Lyn Dimer, Kate P Taylor, Peter L Thompson, Sandra C Thompson.   

Abstract

BACKGROUND: We investigated the relationship between Aboriginality and 2-year cardiovascular disease outcomes in non-fatal first-ever myocardial infarction during 2000-04, with progressive adjustment of covariates, including comorbidities.
DESIGN: Historical cohort study.
METHODS: Person-linked hospital and mortality records were used to identify 28-day survivors of first-ever myocardial infarction in Western Australia during 2000-04 with 15-year lookback. The outcome measures were: (1) cardiovascular disease death; (2) recurrent admission for myocardial infarction; and (3) the composite of (1) and (2).
RESULTS: Compared with non-Aboriginal patients, Aboriginals were younger and more likely to live remotely. The proportions having 5-year histories of diabetes and chronic kidney disease were double and triple those of non-Aboriginals. When adjusting for demographic variables alone, the Aboriginal to non-Aboriginal hazard ratios for cardiovascular death or recurrent myocardial infarction were 3.6 (95% CI 2.5-5.3) in men and 4.5 (95% CI 2.8-7.3) in women. After adjustment for comorbidities, including diabetes, chronic kidney disease and heart failure, the hazard ratios decreased 36% and 47% to 2.3 (1.6-3.0) and 2.4 (1.5-4.0) in males and females, respectively.
CONCLUSIONS: The high prevalence of comorbidities in Aboriginal people, including diabetes, kidney disease, heart failure, and other risk factors contribute substantially to the disparity in post-myocardial infarction outcomes in Aboriginal people, reinforcing the importance of both primary prevention and comprehensive management of chronic conditions in this population. Aboriginality remains a significant independent risk factor for disease recurrence or mortality, even after adjusting for comorbidity, suggesting the need for society-level interventions addressing social disadvantage.

Entities:  

Mesh:

Year:  2011        PMID: 21798989     DOI: 10.1177/1741826711417925

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  12 in total

1.  Mortality after admission for acute myocardial infarction in Aboriginal and non-Aboriginal people in New South Wales, Australia: a multilevel data linkage study.

Authors:  Deborah A Randall; Louisa R Jorm; Sanja Lujic; Aiden J O'Loughlin; Timothy R Churches; Mary M Haines; Sandra J Eades; Alastair H Leyland
Journal:  BMC Public Health       Date:  2012-04-10       Impact factor: 3.295

2.  Concordance between administrative health data and medical records for diabetes status in coronary heart disease patients: a retrospective linked data study.

Authors:  Lee Nedkoff; Matthew Knuiman; Joseph Hung; Frank M Sanfilippo; Judith M Katzenellenbogen; Tom G Briffa
Journal:  BMC Med Res Methodol       Date:  2013-10-01       Impact factor: 4.615

3.  Disparities experienced by Aboriginal compared to non-Aboriginal metropolitan Western Australians in receiving coronary angiography following acute ischaemic heart disease: the impact of age and comorbidities.

Authors:  Derrick Lopez; Judith M Katzenellenbogen; Frank M Sanfilippo; John A Woods; Michael S T Hobbs; Matthew W Knuiman; Tom G Briffa; Peter L Thompson; Sandra C Thompson
Journal:  Int J Equity Health       Date:  2014-10-21

4.  Is the incidence of heart attack still decreasing in Australia? Developing reliable methods for monitoring trends in myocardial infarction and coronary heart disease (AUS-MOCHA): a study protocol.

Authors:  Lee Nedkoff; Matthew Knuiman; Michael S T Hobbs; Joseph Hung; Sushma Mathur; John Beilby; Anna Reynolds; Tom G Briffa; Derrick Lopez; Frank M Sanfilippo
Journal:  BMJ Open       Date:  2016-08-24       Impact factor: 2.692

5.  Improving cardiovascular outcomes among Aboriginal Australians: Lessons from research for primary care.

Authors:  Sandra C Thompson; Emma Haynes; John A Woods; Dawn C Bessarab; Lynette A Dimer; Marianne M Wood; Frank M Sanfilippo; Sandra J Hamilton; Judith M Katzenellenbogen
Journal:  SAGE Open Med       Date:  2016-11-29

Review 6.  Heart failure among Indigenous Australians: a systematic review.

Authors:  John A Woods; Judith M Katzenellenbogen; Patricia M Davidson; Sandra C Thompson
Journal:  BMC Cardiovasc Disord       Date:  2012-11-01       Impact factor: 2.298

7.  Voting with their feet--predictors of discharge against medical advice in Aboriginal and non-Aboriginal ischaemic heart disease inpatients in Western Australia: an analytic study using data linkage.

Authors:  Judith M Katzenellenbogen; Frank M Sanfilippo; Michael S T Hobbs; Matthew W Knuiman; Dawn Bessarab; Angela Durey; Sandra C Thompson
Journal:  BMC Health Serv Res       Date:  2013-08-20       Impact factor: 2.655

8.  Transfers to metropolitan hospitals and coronary angiography for rural Aboriginal and non-Aboriginal patients with acute ischaemic heart disease in Western Australia.

Authors:  Derrick Lopez; Judith M Katzenellenbogen; Frank M Sanfilippo; John A Woods; Michael S T Hobbs; Matthew W Knuiman; Tom G Briffa; Peter L Thompson; Sandra C Thompson
Journal:  BMC Cardiovasc Disord       Date:  2014-05-01       Impact factor: 2.298

Review 9.  Heart Failure in Minority Populations - Impediments to Optimal Treatment in Australian Aborigines.

Authors:  Pupalan Iyngkaran; Nadarajan Kangaharan; Hendrik Zimmet; Margaret Arstall; Rob Minson; Merlin C Thomas; Peter Bergin; John Atherton; Peter MacDonald; David L Hare; John D Horowitz; Marcus Ilton
Journal:  Curr Cardiol Rev       Date:  2016

Review 10.  Contextualizing Genetics for Regional Heart Failure Care.

Authors:  Pupalan Iyngkaran; Merlin C Thomas; Renee Johnson; John French; Marcus Ilton; Peter McDonald; David L Hare; Diane Fatkin
Journal:  Curr Cardiol Rev       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.